Chemotherapy-Induced Myelosuppression in SCLC
Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC Receiving Single-Agent Lurbinectedin in the Phase 3 ATLANTIS Trial
By
ASCO 2022 Conference Coverage
FEATURING
Alejandro Navarro
By
ASCO 2022 Conference Coverage
FEATURING
Alejandro Navarro
Comments 0
Login to view comments.
Click here to Login